Departments of Cellular and Physiological Sciences and Obstetrics and Gynaecology, The University of British Columbia, Vancouver, British Columbia, Canada.
Endocrine Unit, Second Department of Internal Medicine-Research Institute and Diabetes Center, Attiko University Hospital, Athens, Greece.
J Endocrinol. 2019 Jan 1;240(1):27-39. doi: 10.1530/JOE-18-0479.
Corticosteroid-binding globulin (CBG) transports glucocorticoids in blood and is a serine protease inhibitor family member. Human CBG has a reactive center loop (RCL) which, when cleaved by neutrophil elastase (NE), disrupts its steroid-binding activity. Measurements of CBG levels are typically based on steroid-binding capacity or immunoassays. Discrepancies in ELISAs using monoclonal antibodies that discriminate between intact vs RCL-cleaved CBG have been interpreted as evidence that CBG with a cleaved RCL and low affinity for cortisol exists in the circulation. We examined the biochemical properties of plasma CBG in samples with discordant ELISA measurements and sought to identify RCL-cleaved CBG in human blood samples. Plasma CBG-binding capacity and ELISA values were consistent in arterial and venous blood draining skeletal muscle, liver and brain, as well as from a tissue (adipose) expected to contain activated neutrophils in obese individuals. Moreover, RCL-cleaved CBG was undetectable in plasma from critically ill patients, irrespective of whether their ELISA measurements were concordant or discordant. We found no evidence of RCL-cleaved CBG in plasma using a heat-dependent polymerization assay, and CBG that resists immunoprecipitation with a monoclonal antibody designed to specifically recognize an intact RCL, bound steroids with a high affinity. In addition, mass spectrometry confirmed the absence of NE-cleaved CBG in plasma in which ELISA values were highly discordant. Human CBG with a NE-cleaved RCL and low affinity for steroids is absent in blood samples, and CBG ELISA discrepancies likely reflect structural differences that alter epitopes recognized by specific monoclonal antibodies.
皮质类固醇结合球蛋白(CBG)在血液中转运糖皮质激素,是丝氨酸蛋白酶抑制剂家族的一员。人 CBG 具有反应中心环(RCL),当被中性粒细胞弹性蛋白酶(NE)切割时,会破坏其类固醇结合活性。CBG 水平的测量通常基于类固醇结合能力或免疫测定。使用区分完整 CBG 与 RCL 切割 CBG 的单克隆抗体的 ELISA 之间存在差异,这些差异被解释为存在具有切割的 RCL 和对皮质醇亲和力低的循环 CBG 的证据。我们检查了具有不一致 ELISA 测量的血浆 CBG 的生化特性,并试图在人血样中鉴定 RCL 切割的 CBG。动脉和静脉血液从骨骼肌、肝脏和大脑引流,以及从肥胖个体中预期含有活化中性粒细胞的组织(脂肪)中,CBG 的血浆结合能力和 ELISA 值是一致的。此外,无论其 ELISA 测量值是否一致,重症患者的血浆中均无法检测到 RCL 切割的 CBG。我们使用依赖热的聚合测定法在血浆中未发现 RCL 切割的 CBG,并且用设计用于特异性识别完整 RCL 的单克隆抗体抵抗免疫沉淀的 CBG 与类固醇具有高亲和力结合。此外,质谱证实了 ELISA 值高度不一致的血浆中不存在 NE 切割的 CBG。血液样本中不存在具有 NE 切割的 RCL 和对类固醇亲和力低的人 CBG,而 CBG ELISA 差异可能反映了改变特定单克隆抗体识别的表位的结构差异。